Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLAXF SEC filings page on Stock Titan provides access to US regulatory documents filed by GSK plc, a global biopharma company. As a foreign private issuer, GSK submits an annual Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934. These filings, sourced from EDGAR, cover product approvals, clinical trial outcomes, regulatory milestones and detailed transaction notifications for persons discharging managerial responsibilities (PDMRs).
For investors analysing GLAXF, GSK’s 6-K reports are a primary source of information on its vaccines, respiratory and immunology portfolio, and infectious disease pipeline. Recent filings describe European Commission approval of a prefilled syringe presentation for Shingrix, GSK’s recombinant zoster vaccine, and regulatory approvals in Japan for Exdensur (depemokimab) in severe asthma and chronic rhinosinusitis with nasal polyps. Other 6-Ks outline phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, including definitions of functional cure and key efficacy findings.
GSK’s filings also contain structured PDMR transaction notifications. These tables specify the financial instrument (ordinary shares of 31¼ pence each), ISIN (GB00BN7SWP63), nature of the transaction (such as acquisition of shares via dividend reinvestment or share reward plans), price, volume, date and trading venue (London Stock Exchange). This information allows users to track insider-related share dealings through Form 6-K disclosures.
On Stock Titan, each new GSK 6-K or 20-F is captured and can be paired with AI-powered summaries that explain the main points in plain language. Users can quickly identify filings related to vaccines, respiratory biologics, hepatology candidates or PDMR share activity, and then drill into the original documents for full legal and scientific detail.
GSK plc reports that on 10 December 2025 it repurchased 220,000 ordinary shares of 31¼ pence each under its existing share buyback programme, acting through BNP Paribas SA. The shares were bought at prices between 1,771.00p and 1,807.00p per share, with a volume-weighted average price of 1,789.73p.
The repurchased shares will be held as treasury shares. Since 30 September 2025, GSK has bought a total of 12,944,733 ordinary shares under this programme. After this transaction, GSK holds 238,409,577 shares in treasury and has 4,077,029,560 ordinary shares in issue, which is also the total number of voting rights in the company. GSK states that treasury shares now represent 5.85% of its voting rights.
GSK plc reports that it repurchased 250,000 of its ordinary shares on 9 December 2025 through BNP Paribas SA under its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 1,780.00p and 1,820.00p, at a volume‑weighted average price of 1,800.43p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased a total of 12,724,733 ordinary shares under this programme. After the latest transactions, the company holds 238,189,577 shares in treasury and has 4,077,249,560 ordinary shares in issue, which also represents the total number of voting rights. GSK states that, in line with regulatory rules, treasury shares now account for 5.84 per cent of the company’s voting rights, a figure shareholders can use when calculating disclosure thresholds.
GSK plc reports that its B7-H3-targeted antibody-drug conjugate GSK'227, now called risvutatug rezetecan, has received Orphan Drug Designation from the US FDA for treating small-cell lung cancer (SCLC). This decision is based on early phase I ARTEMIS-001 data showing durable responses in patients with extensive-stage SCLC, a form of the disease with high relapse rates, few treatment options and a five-year survival rate of about 3%.
This is the fifth major regulatory designation for risvutatug rezetecan, following EMA Orphan Drug Designation in pulmonary neuroendocrine carcinoma, EMA PRIME status in relapsed extensive-stage SCLC, and two US FDA Breakthrough Therapy Designations in relapsed or refractory ES-SCLC and osteosarcoma. GSK has begun a global phase III trial in relapsed extensive-stage SCLC, positioning this investigational therapy as a key part of its oncology pipeline.
GSK plc reported a share transaction by a senior manager. Sally Jackson, SVP, Global Communications & CEO Office, sold 6,000 ordinary shares of GSK on the London Stock Exchange. The shares were sold at a price of £18.2870 per share on 2025-12-05. This disclosure is a routine notification of dealings by a person discharging managerial responsibilities in GSK’s securities.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 229,000 ordinary shares on 8 December 2025 as part of its existing share buyback programme. The shares, each with a nominal value of 31¼ pence, were bought at prices between 1,803.00p and 1,822.00p per share, with a volume‑weighted average price of 1,814.42p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought back a total of 12,474,733 ordinary shares. After this latest transaction, it holds 237,939,577 shares in treasury and has 4,077,499,560 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights represented by the treasury shares is 5.84%, a reference figure for investors monitoring notification thresholds under UK disclosure rules.
GSK plc reports that on 05 December 2025 it repurchased 248,000 of its ordinary shares of 31¼ pence each through BNP Paribas SA under its existing share buyback programme. The shares were bought at prices between 1,798.00p and 1,833.00p per share, with a volume-weighted average price of 1,818.74p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought back a total of 12,245,733 ordinary shares. Following this latest purchase, the company holds 237,710,577 shares in treasury and has 4,077,728,560 ordinary shares in issue, which is also the total number of voting rights. GSK states that treasury shares now represent 5.83% of its voting rights, a figure shareholders can use when assessing notification thresholds under UK disclosure rules.
GSK plc reports that it repurchased 233,000 of its ordinary shares of 31¼ pence each on 4 December 2025 under its existing share buyback programme, using BNP Paribas SA as broker. The shares were bought at prices between 1,819.00p and 1,852.50p per share, with a volume-weighted average price of 1,832.36p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought 11,997,733 ordinary shares under this programme. After this latest purchase, GSK holds 237,462,577 shares in treasury and has 4,077,971,107 ordinary shares in issue, which is also the total number of voting rights. The company states that, following this transaction, treasury shares represent 5.82% of the voting rights.
GSK plc reports that on 03 December 2025 it repurchased 218,000 ordinary shares of 31¼ pence each through BNP Paribas SA under its existing share buyback programme. The shares were bought at prices between 1,830.00p and 1,848.00p, with a volume-weighted average price of 1,839.30p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 11,764,733 ordinary shares under this programme. After this latest transaction, GSK holds 237,229,577 ordinary shares in treasury and has 4,078,204,107 ordinary shares in issue, giving a total of 4,078,204,107 voting rights. The percentage of voting rights attributable to treasury shares is stated as 5.82 per cent.
GSK plc reports that on 02 December 2025 it repurchased 200,000 of its ordinary shares of 31¼ pence each through BNP Paribas SA as part of its existing share buyback programme. The shares were bought at prices between 1,783.00p and 1,827.00p, with a volume-weighted average price of 1,815.48p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased a total of 11,546,733 ordinary shares under this programme. After the latest transaction, the company holds 237,011,577 shares in treasury and has 4,078,422,107 ordinary shares in issue, which is also the total number of voting rights. GSK states that treasury shares represent 5.81 per cent of the voting rights, a figure relevant for shareholders’ disclosure calculations under UK rules.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 203,000 ordinary shares on 01 December 2025 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 1,786.00p and 1,810.00p, with a volume-weighted average price of 1,800.44p.
After this transaction, GSK holds 236,811,577 ordinary shares in treasury and has 4,078,622,107 ordinary shares in issue excluding treasury shares. The total number of voting rights in GSK is 4,078,622,107, and the company states that treasury shares represent 5.81% of the voting rights, which shareholders can use as a reference for regulatory disclosure thresholds.
FAQ
What is the current stock price of GSK PLC (GLAXF)?
